A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
Inclusion Criteria:
Exclusion Criteria
CABA, Buenos Aires C1120AAC, Argentina
CABA, Buenos Aires C1179AAB, Argentina
CABA, Buenos Aires C1204AAD, Argentina
Rosario, Buenos Aires S2000BIF, Argentina
Ciudad Autónoma de Buenos Aire, C1440AAD, Argentina
São Bernardo do Campo, São Paulo 09715-090, Brazil
São José dos Campos, São Paulo 12243-280, Brazil
Saint Ingbert, Saarland 66386, Germany
N. Efkarpia, Thessaloniki 56403, Greece
Saint Petersburg, 194354, Russia
Adana, 01240, Turkey (Türkiye)